A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (Anti?pd-l1 antibody) IN patients with UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (Anti?pd-l1 antibody) IN patients with UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.